These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21937968)

  • 1. Pharmacogenetics and the pharmacological management of depression.
    Krauter RR; Cook SS
    Nurse Pract; 2011 Oct; 36(10):14-21; quiz 21-2. PubMed ID: 21937968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.
    Breil F; Verstuyft C; Orostegui L; Buhl C; Alvarez JC; Chouinard G; Becquemont L; Corruble E
    Int J Neuropsychopharmacol; 2008 Aug; 11(5):727-8. PubMed ID: 18384706
    [No Abstract]   [Full Text] [Related]  

  • 3. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
    Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
    Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.
    Vandel P
    World J Biol Psychiatry; 2003 Apr; 4(2):74-80. PubMed ID: 12692778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity.
    Wijnen PA; Limantoro I; Drent M; Bekers O; Kuijpers PM; Koek GH
    Ann Clin Biochem; 2009 Nov; 46(Pt 6):527-30. PubMed ID: 19822698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
    Zourková A; Hadasová E
    Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy.
    Mirzakhani H; van Dormolen J; van der Weide K; Guchelaar HJ; van Noorden MS; Swen J
    Pharmacogenet Genomics; 2015 Oct; 25(10):515-7. PubMed ID: 26230381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
    Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
    Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype].
    Grzesiak M; Beszłej A; Lebioda A; Jonkisz A; Dobosz T; Kiejna A
    Psychiatr Pol; 2003; 37(3):433-44. PubMed ID: 13677973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity.
    Zourková A; Cesková E; Hadasová E; Ravcuková B
    J Sex Marital Ther; 2007; 33(4):343-55. PubMed ID: 17541852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacogenetics of depression in elderly patients].
    Monnin J; Haffen E; Sechter D; Vandel P
    Psychol Neuropsychiatr Vieil; 2009 Mar; 7(1):43-55. PubMed ID: 19251571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of pharmacogenomic testing in psychiatry: Real world examples.
    Dinama O; Warren AM; Kulkarni J
    Aust N Z J Psychiatry; 2014 Aug; 48(8):778. PubMed ID: 24413808
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
    Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG
    Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxepin inhibits CYP2D6 activity in vivo.
    Szewczuk-Bogusławska M; Kiejna A; Beszłej JA; Orzechowska-Juzwenko K; Milejski P
    Pol J Pharmacol; 2004; 56(4):491-4. PubMed ID: 15520506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression.
    Dubovsky SL
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):369-79. PubMed ID: 25554071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.
    Lee SY; Ki CS; Hong KS; Kim JW
    J Korean Med Sci; 2004 Oct; 19(5):750-2. PubMed ID: 15483356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
    Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T
    Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.